Basarir H, Mauskopf J, McCrink L, Karmarkar T, O'Brien M. A systematic literature review of rationale, methods, and use of cost-effectiveness thresholds in health technology assessments. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S330-1. doi: 10.1016/j.jval.2022.09.1634
Spentzouris G, Bilitou A, Manga N, McCrink L, Pearson I, Mitchell S, Moss E, Rothwell B. Systematic literature review of cost and data sources for economic evaluations in hypercholesterolaemia and mixed dyslipidaemia from a UK perspective. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011 Jul 1;22(7):2083-98.
McCrink L, Allen RP, Wolowacz SE, Sherrill B, Connolly M, Kirsch J. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med. 2007 Jan 1;8(1):73-83.
McCrink L, Beard SM, Le T. The relationship between health-related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A41.
McCrink L, Beard S, Le TK. The relationship between health related quality of life (HRQOL) and pain response in patients with diabetic peripheral neuropathic pain (DPNP). Value Health. 2006 May 1;9(3):A41.
von Scheele B, David K, Gaffney L, Niculescu L, Verburg KM. The total cost of treatment and the cost-effectiveness of valdecoxib vs diclofenac in the treatment of patients with osteoarthritis (OA) of the hip and/or knee. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):661.
Earnshaw SR, Beard SM, Gaffney L, Krishnan A, Hogue SL. The impact of premature discontinuation of antidepressant therapy in major depressive disorder in the UK. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):A779.
Alten RH, von Scheele B, Gaffney L, Maciver F, Niculescu L. Cost-effectiveness of valdecoxib compared to diclofenac in patients with rheumatoid arthiritis (RA) in the United Kingdom (UK) and Germany. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6).
Beard SM, Wall L, Gaffney L, Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004 Jan 1;22(4):207-24.
Beard SM, Gaffney L, Bamber L. Economic modelling of antiplatelet therapy in the secondary prevention of stroke. Poster presented at the 2003 ISPOR 6th Annual European Congress; November 9, 2003. Barcelona, Spain.
von Scheele B, DePlatchett J, Gaffney L, Peña BM, Niculescu L. The total costs of treatment with valdecoxib compared to generic diclofenac are similar in patients with rheumatoid arthritis in Germany. Poster presented at the 2003 ISPOR 6th Annual European Congress; November 9, 2003. Barcelona, Spain. [abstract] Value Health. 2003 Nov; 6(6):725-6.
Beard S, Gaffney L, Bamber L. Economic modelling of antiplatelet therapy in the prevention of recurrent stroke. Value Health. 2003 Jan 1;6(6):650.
Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. J Med Econ. 2001 Jan 1;4:199-205.